Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: In vitro and in vivo studies

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 2, 2001, Pages 175-182

  Shintani, Masayuki ^a,b,c   Ieiri, Ichiro ^a,b,c   Inoue, Kazuko ^a,b,c   Mamiya, Kohsuke ^a,b,c   Ninomiya, Hideaki ^a,b,c   Tashiro, Nobutada ^a,b,c   Higuchi, Shun ^a,b,c   Otsubo, Kenji ^a,b,c  

^a Division of Pharmaceutical Sciences   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; DNA; PHENYTOIN;

ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA FLANKING REGION; DRUG METABOLISM; EPILEPSY; EVALUATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; SEQUENCE ANALYSIS;

ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BAYES THEOREM; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; FEMALE; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; MUTATION; PHENOTYPE; PHENYTOIN; PLASMIDS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; VARIATION (GENETICS);

EID: 0034892729     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.117367     Document Type: Article

References (25)

1. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
2. The effect of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereo-selective hydroxylation and population pharmacokinetics
3. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
4. Genetic analysis of the human cytochrome P-450 CYP2C9 locus
5. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus
6. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis
7. A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake
8. Structural and functional characterization of the 5′-flanking region of the rat and human cytochrome P450 2E1 genes: Identification of a polymorphic repeat in the human gene
9. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans
10. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region
11. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18
12. Identification of a novel transcriptional silence in the protein-coding region of the human CYP2C9 gene
13. Transcriptional regulation of human CYP2C genes: Functional comparison of CYP2C9 and CYP2C18 promoter regions
14. The role of cis-acting promoter elements in tissue-specific albumin gene expression
15. HNF-1 shares three sequence motifs with the POU domain proteins and is identical to LF-B1 and APF
16. CCAAT/enhancer binding protein activates the promoter of the serum albumin gene in cultured hepatoma cells
17. The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite
18. Binding of a liver-specific factor to the human albumin gene promoter and enhancer
19. Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters
20. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
21. Role of the liver-enriched transcription factor HNF-1α in expression of the CYP2E1 gene
22. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
23. A mutation in CYP2C9 is responsible for decreased metabolism of losartan
24. Elucidation of the genetic basis of the common "intermediate metabolizers" phenotype for drug oxidation by CYP2D6
25. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication